| Summary: | 1. Some pregnant women have antibodies to (have become immunised against) the blood group of the fetus, which represents a risk to the fetus. The use of NIPD to determine the blood group of the fetus may help to improve the safety of medical care offered to these women and their unborn children.2. Screening for fetal blood group using NIPD, in combination with specific prenatal preventive measures (targeted RhD prophylaxis), could result in fewer RhD-negative pregnant women developing antibodies to RhD. The organisational and health economic consequences of introducing this type of screening have not been established.3. The use of NIPD to determine fetal sex when this is medically justified could improve the safety of medical care by reducing the need for invasive fetal diagnostic tests. The technique is not currently used for this purpose in Sweden.4. There is a lack of published research into the cost-effectiveness of using NIPD to determine fetal sex or blood group
|
|---|